Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - CNS tumours

3570 - Hypothyroidism is associated with improved survival prognosis in patients with newly diagnosed brain metastases

Date

20 Oct 2018

Session

Poster Discussion session - CNS tumours

Presenters

Christoph Wippel

Citation

Annals of Oncology (2018) 29 (suppl_8): viii122-viii132. 10.1093/annonc/mdy273

Authors

C. Wippel1, A.M. Starzer1, A.S. Berghoff2, E. Bergen1, P. Wolf3, G. Widhalm4, J.M. Frischer4, B. Gatterbauer4, C. Marosi1, K. Dieckmann5, R. Bartsch1, M. Preusser6

Author affiliations

  • 1 Department Of Medicine I - Clinical Division Of Oncology, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 2 Department Of Medicine 1, Medical University of Vienna, 1090 - Vienna/AT
  • 3 Department Of Medicine Iii, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 4 Department Of Neurosurgery, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 5 Department Of Radiotherapy, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 6 Department Of Medicine I, Medical University of Vienna, Vienna, Austria, 1090 - Vienna/AT
More

Resources

Abstract 3570

Background

Thyroid hormones may have tumor promoting effects due to the increased activity of phosphatidylinositol-3-kinase and induction of angiogenesis. Lower TSH levels, representing excessive thyroid function, were associated with increased risk for several tumor types, whereas hypothyroidism was shown to have the opposite effect. However, only limited knowledge exists on the prognostic impact in patients with advanced cancer. Given the difficulties in prognostic assessment in patients with newly diagnosed brain metastases (BM) we aimed to investigate the prognostic impact of thyroid function.

Methods

Patients with newly diagnosed BM were identified from the Vienna Brain Metastasis Registry and clinical data including survival data, thyroid stimulating hormone (TSH) and free thyroxine (fT4) were retrieved by chart review.

Results

265 patients (191/265 (72.1%) non-small cell lung cancer; 74/265 (27.9%) triple negative breast cancer) with a median age of 59 years (range 26-85) at diagnosis of BM were available for analysis. 22/265 (8.3%) patients presented with a history of hypothyroidism prior to diagnosis while 5/265 (1.9%) patients presented with hyperthyroidism. While history of hyperthyroidism was not associated with survival prognosis (p = 0.487; log rank test), patients with hypothyroidism had an improved survival prognosis upon BM diagnosis (8 vs. 14 months; p = 0.032; log rank test). Pre-existing hypothyroidism presented with independent statistically significant association with survival prognosis (HR 0.6; 95% CI 0.4-0.9; p = 0.025) in multivariate analysis including GPA class (HR 1.6; 95% CI 1.3-1.9; p < 0.001) and tumor type (HR 1.5; 95% 1.1-2.0; p = 0.006).

Conclusions

Preexisting hypothyroidism had a strong and independent prognostic impact in patients with newly diagnosed BM underscoring the evidence from pre-clinical data that thyroid hormones might indeed impact tumor growth. Further investigation of the underlying mechanism is warranted to identify a possible therapeutic impact.

Clinical trial identification

Legal entity responsible for the study

Medical University of Vienna.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings